# Michael Choukas

> Michael Choukas is the co-founder and CEO of Autem Therapeutics, a Hanover, New Hampshire biotech building AutEMsys, a bioelectric platform that delivers personalized, amplitude-modulated electromagnetic frequencies to treat solid tumor cancers. A Dartmouth and Harvard Business School graduate, he spent two decades running clinical-development, real-world-data, and oncology-analytics businesses at firms like ConcertAI, Vector Oncology, United BioSource, SCIREX and Bain & Company, work he credits with more than $2.5 billion in market value creation. He raised a $10 million Series A-1 in 2022 and is steering Autem toward FDA-cleared trials in liver cancer and glioblastoma.

- **Role:** Co-founder and Chief Executive Officer at Autem Therapeutics
- **Organizations:** Autem Therapeutics, ConcertAI (Concerto HealthAI), Vector Oncology, United BioSource (UBC), SCIREX, Bain & Company, Oncopartners
- **Nationality:** American
- **Education:** B.A., Dartmouth College, M.B.A., Harvard Business School
- **Known for:** Co-founded Autem Therapeutics and built a globally distributed team spanning the USA, Brazil, Germany and Canada, Raised a $10 million Series A-1 round for Autem in 2022, Helped guide AutEMsys to FDA Breakthrough Device designation for advanced hepatocellular carcinoma

## Career timeline

- **—** — Began his career as a consultant at Bain & Company
- **—** — Held leadership roles at SCIREX and United BioSource (UBC) in clinical development and real-world data analytics
- **—** — Served as CEO of Vector Oncology, an oncology real-world data and analytics company
- **—** — Became President of Outcomes Science and Services at Concerto HealthAI (now ConcertAI)
- **2022** — Co-founded Autem Therapeutics with Frederico Costa, MD, and became CEO
- **2022** — Led Autem's $10 million Series A-1 financing round, led by Zentynel Frontier Investments
- **2024** — Closed an additional Series A round of approximately $1.5 million
- **2025** — Autem targeted FDA Investigational Device Exemption approvals to begin clinical trials in HCC and glioblastoma; Choukas featured as a startup founder in the VCIC MBA Northeast competition

## Achievements

- Co-founded Autem Therapeutics and built a globally distributed team spanning the USA, Brazil, Germany and Canada
- Raised a $10 million Series A-1 round for Autem in 2022
- Helped guide AutEMsys to FDA Breakthrough Device designation for advanced hepatocellular carcinoma
- Credited with contributing to more than $2.5 billion in market value creation across his company-building career
- Served as President at ConcertAI and CEO of its predecessor Vector Oncology

## Latest updates

- **2025** — Autem worked toward FDA Investigational Device Exemption approvals to launch clinical trials in HCC and glioblastoma, and refreshed its leadership team.
- **2024-02** — Closed an additional Series A financing of roughly $1.5 million.

## Links

- Website: https://autemtherapeutics.com
- LinkedIn: https://www.linkedin.com/in/michael-choukas-04b1bb49/

---

Profile page: https://yespress.io/michael-choukas
Published by YesPress — https://yespress.io
Last updated: 2026-06-10